GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt · Delayed Price · Currency is EGP 331.44
-82.86 (-20.00%)
At close: Aug 5, 2026
GlaxoSmithKline S.A.E Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 213.23 | 173.98 | 60.46 | 735.38 | 154.64 |
Depreciation & Amortization | 61.47 | 52.92 | 47.79 | 49.81 | 57.19 |
Loss (Gain) From Sale of Assets | -0.48 | 2.4 | -0.17 | -5.94 | -0.24 |
Asset Writedown & Restructuring Costs | - | - | 137.65 | 101 | - |
Loss (Gain) on Equity Investments | -35.3 | -1 | 18.12 | -12.15 | 9.21 |
Provision & Write-off of Bad Debts | -5.32 | 64.64 | -18.66 | 11.01 | 30.79 |
Other Operating Activities | 230.83 | 386.52 | 24.11 | -530.26 | 89.78 |
Change in Accounts Receivable | -142.62 | -333.87 | -366.5 | -231.15 | -18.53 |
Change in Inventory | -649.32 | -420.25 | -263.59 | -47.2 | -42.95 |
Change in Accounts Payable | 142.09 | 64.9 | 156.24 | -322.32 | 45.45 |
Change in Other Net Operating Assets | 426.25 | -394.38 | 506.84 | -82.97 | -133.15 |
Operating Cash Flow | 240.83 | -404.15 | 302.27 | 1,036 | 192.19 |
Operating Cash Flow Growth | - | - | -70.82% | 439.06% | - |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -177.28 | -124.34 | -77.08 | -48.76 | -35.76 |
Sale of Property, Plant & Equipment | 0.61 | - | 5.42 | 6.99 | 0.61 |
Other Investing Activities | 292.05 | -101.72 | 157.15 | -200 | - |
Investing Cash Flow | 115.39 | -226.07 | 85.5 | -241.77 | -35.15 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Repaid | - | - | - | -118.21 | -27.52 |
Long-Term Debt Repaid | -43.06 | -43.38 | -28.98 | -19.21 | -24.11 |
Total Debt Repaid | -43.06 | -43.38 | -28.98 | -137.43 | -51.63 |
Net Debt Issued (Repaid) | -43.06 | -43.38 | -28.98 | -137.43 | -51.63 |
Common Dividends Paid | -14.13 | -69.67 | -131.59 | -111.04 | -5.58 |
Other Financing Activities | 105.18 | -10.6 | 16.3 | -33.5 | -48.42 |
Financing Cash Flow | 48 | -123.66 | -144.28 | -281.97 | -105.63 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 404.22 | -753.87 | 243.49 | 512.29 | 51.41 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 63.55 | -528.49 | 225.2 | 987.26 | 156.43 |
Free Cash Flow Growth | - | - | -77.19% | 531.14% | - |
Free Cash Flow Margin | 1.70% | -17.67% | 10.05% | 54.15% | 8.63% |
Free Cash Flow Per Share | 0.76 | -6.33 | 2.70 | 11.82 | 1.87 |
Levered Free Cash Flow | 319.89 | -523.15 | 178.77 | 108.37 | 49.65 |
Unlevered Free Cash Flow | 327.15 | -516.53 | 202.5 | 129.31 | 80.07 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 3.35 | 10.6 | 37.96 | 33.5 | 48.67 |
Cash Income Tax Paid | 108.42 | 48.27 | 173.04 | 10.72 | 29.97 |
Change in Working Capital | -223.6 | -1,084 | 32.99 | -683.64 | -149.18 |